Refine
Has Fulltext
- yes (57)
Is part of the Bibliography
- yes (57)
Year of publication
Document Type
- Journal article (57) (remove)
Language
- English (57)
Keywords
- blood vessel (3)
- cancer (3)
- inflammation (3)
- organoid (3)
- TGFβ signaling (2)
- angiogenesis (2)
- diabetic retinopathy (2)
- expression (2)
- extracellular matrix (2)
- in vitro (2)
Institute
- Institut für Anatomie und Zellbiologie (57)
- Institut für diagnostische und interventionelle Radiologie (Institut für Röntgendiagnostik) (11)
- Klinik und Poliklinik für Allgemein-, Viszeral-, Gefäß- und Kinderchirurgie (Chirurgische Klinik I) (5)
- Klinik und Poliklinik für Unfall-, Hand-, Plastische und Wiederherstellungschirurgie (Chirurgische Klinik II) (4)
- Deutsches Zentrum für Herzinsuffizienz (DZHI) (3)
- Medizinische Klinik und Poliklinik I (3)
- Abteilung für Funktionswerkstoffe der Medizin und der Zahnheilkunde (2)
- Graduate School of Life Sciences (2)
- Institut für Experimentelle Biomedizin (2)
- Institut für Pharmakologie und Toxikologie (2)
Sonstige beteiligte Institutionen
EU-Project number / Contract (GA) number
- 701983 (1)
Clinical prognosis of metastasized colorectal carcinoma (CRC) is still not at desired levels and novel drugs are needed. Here, we focused on the multi-tyrosine kinase inhibitor E7080 (Lenvatinib) and assessed its therapeutic efficacy against human CRC cell lines in vitro and human CRC xenografts in vivo. The effect of E7080 on cell viability was examined on 10 humanCRCcell lines and humanendothelial cells (HUVEC). The inhibitory effect of E7080 on VEGF-induced angiogenesis was studied in an ex vivo mouse aortic ring angiogenesis assay. In addition, the efficacy of E7080 against xenografts derived fromCRC cell lines and CRC patient resection specimenswithmutated KRASwas investigated in vivo. Arelatively low cytotoxic effect of E7080 on CRC cell viabilitywas observed in vitro. Endothelial cells (HUVEC)weremore susceptible to the incubation with E7080. This is in line with the observation that E7080 demonstrated an anti-angiogenic effect in a three-dimensional ex vivo mouse aortic ring angiogenesis assay. E7080 effectively disrupted CRC cell-mediated VEGF-stimulated growth of HUVEC in vitro. Daily in vivo treatment with E7080 (5 mg/kg) significantly delayed the growth of KRAS mutated CRC xenografts with decreased density of tumor-associated vessel formations and without tumor regression. This observation is in line with results that E7080 did not significantly reduce the number of Ki67-positive cells in CRC xenografts. The results suggest antiangiogenic activity of E7080 at a dosage thatwas well tolerated by nudemice. E7080 may provide therapeutic benefits in the treatment of CRC with mutated KRAS.